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PREFACE
The UNODC publication Terminology and Information on Drugs introduces basic concepts 
and materials on substances under international control, which are most frequently 
manufactured or processed and/or abused, as well as definitions of scientific terms 
used in this context. The current revision of this publication is being prepared as a 
response to changes in drug markets and scheduling decisions of the Commission on 
Narcotic Drugs in recent years.
The publication is neither exhaustive, nor meant to replace more comprehensive 
textbooks on drugs of abuse. It seeks to collate basic concepts and information on 
drugs of abuse, their corresponding abuse patterns, pharmacological effects and 
potential medical use, and act as an accessible and user-friendly resource. The format 
of this publication is kept simple to allow for brevity. Comments and suggestions for 
improving content and/or format of this publication by readers are welcome. 
Explanatory note
1. Lists of common substances, illicit forms and street names are not extensive 
listings, but selections. Street names can be ambiguous, and should not be relied 
upon to characterize a given drug.
2. Sections on chemical constituents of cannabis plant, coca bush and opium poppy 
are not comprehensive listings, but focus on those substances which are of interest 
from a drug control point of view. For more detailed chemical information on the 
substances, the reader is directed to the information mentioned in the monographs 
of the Multilingual Dictionaries1,2 and the Clandestine Manufacture of Substances 
under International Control (ST/NAR/10/REV.3) manual. 
3. The mechanism of action and resulting effects listed are a summary of the most 
widely recognized desired effects, undesired acute effects and effects due to 
chronic use of a given substance or group of substances. 
4. In order to make the publication more accessible, related information has been 
displayed in similar tabular forms across each chapter. The following sample shows 
the format of these tables.
1 Multilingual Dictionary of Narcotic Drugs and Psychotropic Substances under International Control, United 
Nations publication, 2006 (Sales No. M.06.XI.16). 
2 Multilingual Dictionary of Precursors and Chemicals Frequently used in the Illicit Manufacture of  Narcotic Drugs 
and Psychotropic Substances under International Control, United Nations publication, 2015 (ST/NAR/1A*/Rev.1).
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Sample formats of tables
Common street names
Mechanism of 
action and 
resulting 
effects
Commonly used 
forms of substances 
and their route of 
administration
Common street names
Bazooka Coco Mister Coffee
Big C Coke Nose candy
Blanche Crack Shake
Blow Dust Snow
Cake Flake Star dust
Cane Koks Toot
Charlie Lady White lady
  Commonly  
used forms
  Route of  
administration
Cocaine base White or off-white 
crystalline powder with  
a characteristic odour
Inhalation 
Crack Hard white rocks Inhalation
Desired effects Undesired acute effects Effects of chronic use
• Sense of physical and 
mental well-being, 
exhilaration, euphoria
• Increased alertness and 
energy
• Suppression of hunger
• Increased heart rate and blood 
pressure, faster breathing
• Increased body temperature, 
sweating
• Vasoconstriction, local 
anaesthesia
• Strong psychological 
dependence
• Development of tolerance
• Destruction of tissues in 
nose if insufflated
• Chronic bronchitis if 
smoked
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SCHEDULE I
SCHEDULE IV
SCHEDULE II SCHEDULE III
Substances that are 
highly addictive and 
liable to abuse, or are 
convertible into drugs 
that are similarly 
addictive and liable 
to abuse
(e.g. cannabis, heroin, 
methadone, opium)
Certain drugs listed in 
Schedule I that are 
highly addictive and 
liable to abuse and 
rarely used in medical 
practice
(e.g. cannabis, heroin)
Substances that are 
less addictive and 
liable to abuse than 
those in Schedule I
(e.g. codeine and its 
derivatives)
Preparations 
containing narcotic 
drugs that are 
intended for medical 
use and are unlikely to 
be abused
(e.g. preparations of 
codeine, dihydro-
codeine, propriam)
SCHEDULING OF SUBSTANCES
The schedules in the international drug control treaties were established to classify 
internationally applicable control measures that would ensure the availability of 
certain substances for medical and scientific purposes, while preventing their 
diversion into illicit channels.
In the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol, 
narcotic drugs and their preparations are essentially listed in four schedules according 
to their dependence potential, abuse liability and therapeutic usefulness (figure 1) [1].3
Figure 1. Single Convention on Narcotic Drugs of 1961
3 See E/CN.7/2014/10
In the Convention on Psychotropic Substances of 1971, control measures are 
categorized in four schedules, depending on the relationship between the 
therapeutic usefulness and the public health risk of the substances. The four 
schedules use a sliding scale of those two variables: inclusion in Schedule I 
implies high public health risk and low therapeutic utility, and therefore the 
strictest control measures, whereas inclusion in Schedule IV implies the 
opposite: lower public health risk and higher therapeutic utility (see figure 2).4
Figure 2. Convention on Psychotropic Substances of 1971
4See E/CN.7/2014/10
SCHEDULE I SCHEDULE II SCHEDULE III
Substances presenting 
a high risk of abuse, 
posing a particularly 
serious threat to public 
health, which are of 
very little or no 
therapeutic value
(e.g. LSD, MDMA 
[“ecstasy”], mescaline)
Substances presenting 
a risk of abuse, posing 
a serious threat to 
public health, which 
are of low or moderate 
therapeutic value
(e.g. amphetamine 
and ampheta-
mine-type stimulants)
Substances presenting 
a risk of abuse, posing 
a serious threat to 
public health, which 
are of moderate or 
high therapeutic value
(e.g. barbiturates, 
including amobarbital, 
buprenorphine)
SCHEDULE III
Substances presenting 
a risk of abuse, posing 
a minor threat to 
public health, with a 
high therapeutic value
(e.g. tranquilizers, 
analgesics, narcotics, 
including allobarbital, 
diazepam)
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“Cannabis” means the flowering or fruiting tops of the cannabis plant 
(excluding the seeds and leaves when not accompanied by the tops) 
from which the resin has not been extracted, by whatever name they 
may be designated [2].
Cannabis contains a number of chemical substances, however the 
most predominant and only psychoactive substance is (-)-trans-delta-
9-tetrahydrocannabinol (delta-9-THC or THC). 
MAJOR CANNABINOIDS 
Tetrahydrocannabinol (THC)
Cannabidiol (CBD)
Cannabinol (CBN)
O
OH
H
H
delta-9-THC
Cannabis1. 
2 
1.1 CANNABIS PRODUCTS
Cannabis plant
“Cannabis plant” means any plant of the genus Cannabis [2]. The cannabis plant, 
Cannabis sativa L. is a single species but is divided into several subspecies; sativa, 
indica and ruderalis. The cannabis plant, however, exists in many different biological, 
chemical or morphological varieties.  
As a “dioecious” species, the plant can be staminate (male) or pistillate (female). 
However, there are individual cases of “monoecious” plants or hermaphrodites, where 
both sexes coexist on one plant. The term “cannabis” is also generally used to 
describe different products obtained from the cannabis plant.
Cannabis (herb)
Cannabis (herb) is a green or brown dried material, which is listed in Schedule I  
and IV of the Single Convention on Narcotic Drugs of 1961. 
  Commonly  
used forms
  Route of  
administration
Loose material (in a small roll wrapped 
in paper or onto sticks)
Inhalation (smoking, vaporization) 
Ground material (melted in butter, 
producing “cannabutter” for “hash 
brownies”, or “space-cake”; or infused 
with hot water as a drink)
Oral consumption
Cannabis resin
“Cannabis resin” means the separated resin, whether crude or purified, obtained from 
the cannabis plant [2]. Characteristically, cannabis resin is the dried brown or black 
resinous secretion of the flowering tops of the cannabis plant. Cannabis resin is 
placed under Schedule I and IV of the Single Convention on Narcotic Drugs of 1961.
Cannabis herbal material
Common street names
420
Blow
Blunt
Bongo
Dagga
Dimba 
Dope
Doobie
Ganja
Grass
Hash
Hemp
Herb
Joint-sticks
Joint
Kif
Kush
Marie-Jeanne
Marihuana
Marijuana
Mary-Jane
Pot
Sensi
Sinsemilla
Skunk
THC-candy
Weed
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Production
There are a variety of processes and procedures used in different parts of the world to 
extract and concentrate cannabis resin. For example, in South and South-West Asia, 
the following techniques are traditionally used:
• The fruiting and flowering tops are rubbed between the palms of the hand, and 
resin is transferred to the palm. 
• Alternatively, the sticky parts of the plant are brushed against rubber sheets, 
where the resin accumulates. 
• The dried herbal material can also be crushed into a powder, exposed to the sun 
for the resin to melt and later kneaded with wooden rods.
• Another technique is to immerse the plant material in boiling water and remove 
resin from the surface.
  Commonly  
used forms
  Route of  
administration
Fine powder (also compressed into 
slabs)
• Inhalation—either alone, or mixed 
with tobacco
• Oral consumption (in the form of 
food and tea)
Loose or pressed sticky powder 
Resin pressed or rolled into slabs, 
rods, balls or other shapes
Cannabis oil
Cannabis oil is obtained by extraction of the crude plant material, cannabis, or 
cannabis resin with an organic solvent. The extract is then filtered and evaporated  
to give an oil of required consistency. It is tar-like reddish to brown or green viscous 
liquid with high levels of THC.
Cannabis resin
Common street names
Charas
Chira
H
Hash
Hashish
Khif
Pot
Shit
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  Commonly  
used forms
  Route of  
administration
Viscous liquid
• Inhalation—where 1-2 drops are 
put on tobacco, or used within a 
vaporizer
• Oral consumption
Production of cannabis, cannabis resin and oil
Harvesting or drying
Threshing or rubbing
Extract with solvent
Extract with 
solvent
THC content (%)
0.5-5
2-20
10-30
Cannabis plant
Cannabis
“flowering or fruiting tops of 
the cannabis plant”
Cannabis resin
“sticky brown substance 
from flowering tops”
Cannabis oil
POTENCY
Common street names
Butane hash oil
Honey oil
Red oil
Cannabis resin and oil
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The THC content of cannabis varies according to the part of the plant and a number of 
external factors in particular the cultivation conditions and techniques used. In recent 
years, as a result of advances in plant selection and cultivation, which includes the 
use of cloning and indoor hydroponic cultivation (growing plants without soil in water 
or sand in an artificial environment), the content of THC in cannabis has been reported 
to be as high as 20 per cent by weight in certain countries [3, 4]. The average 
percentage of THC in cannabis grown under these conditions is generally lower. 
Cannabis grown using traditional methods or less advanced techniques produces even 
lower percentages of THC [3, 4]. 
Medical use
Products that are currently medically approved for therapeutic use include:
• Nabiximol (Sativex®), a liquid cannabis extract of THC and cannabidiol, which is 
indicated for the treatment of pain and spasticity in multiple sclerosis.
• Dronabinol (Marinol®), a specific synthetic isomer of THC (under Schedule II of 
the Convention on Psychotropic Substances of 1971) [2], is indicated for the 
treatment of loss of appetite in patients with AIDS and for severe nausea and 
vomiting associated with cancer chemotherapy. 
There are a variety of ongoing studies on other cannabinoid products for possible 
therapeutic uses.
Mechanism of action and resulting effects
The psychoactive effects of cannabis are mainly mediated through the activation of  
the cannabinoid type 1 receptors (CB1). Activation of these receptors regulates the 
release of multiple neurotransmitters. Different species of the cannabis plant can  
have different relative effects due to varying THC levels. Nonetheless, further research 
is needed to elucidate the full scope of the pharmacological effects and receptors 
involved.
6 
Desired effects Undesired acute effects Effects of chronic use
• Sense of well-being, 
euphoria—a “high” 
feeling
• Merriment
• Relaxation
• Enhancement of sensory 
experiences, i.e. more 
vivid sense of sight, 
smell, taste and hearing
• Increased heart rate
• Impairment of cognitive 
development (learning), 
including associative 
processes, short-term 
memory, concentration 
and logical thinking
• Impairment of 
psychomotor 
performance (i.e. motor 
coordination, complex 
tasks)
• Potential anxiety, panic, 
paranoia, or acute 
psychosis
• As effects subside, may 
lead to quietness, 
reflectiveness, 
depression or sleepiness
• Reddening of eyes
• Perceptions of sound, 
colour, and other 
sensations may be 
distorted, thinking 
becomes slow and 
confused
• Potential development of 
psychological dependence 
• Development of tolerance 
• Possible mental health 
problems 
• Loss of drive and interest
• May pose a risk of lung 
cancer, acute and chronic 
bronchitis, lung 
inflammation, impaired 
pulmonary defence, and 
other lung diseases 
• Exacerbation of psychosis 
or schizophrenia in 
vulnerable individuals
• Severe risks during use in 
pregnancy, e.g. impaired 
foetal development (a 
reduction in birth weight) 
or postnatal issues 
• Potential development of 
cannabinoid hyperemesis 
syndromea
a Cannabinoid Hyperemesis Syndrome (CHS) is a clinical condition of cyclic episodes of nausea, vomiting and 
abdominal pain, which is caused by long-term or chronic use of cannabinoids
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ENDOGENOUS CANNABINOID RECEPTORS
Early analyses of the main psychoactive component of cannabis, delta-9-THC, led 
to the discovery of endogenous cannabinoid receptors in 1988. The cannabinoid 
receptor type 1 (CB1 ) was first cloned in 1990, whereas CB2 was cloned in 1993. 
Presently, it is known that cannabinoids bind to and activate the CB1 and CB2 
receptors and pharmacological effects are mediated through them. CB1 is mainly 
located in the central nervous system (CNS), the brain and thalamus, while CB2 is 
found outside of the CNS, more peripherally, in the spleen and cells of the 
immune system.
The comprehensive role of receptors in this context in producing pharmacological 
effects is not yet known. However, the activation of these receptors possibly 
results in a number of overlapping effects, as shown in the figure below. 
CB2
PSYCHOACTIVE
EFFECTS:
Memory
Mood
Sleep
Appetite
Pain sensation
PHYSIOLOGICAL 
PROCESSES:
Circulation
Energy metabolism
Organ function
Homeostasis
CB1
Immune 
response
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Synthetic cannabinoid receptor agonists (SCRAs) are substances 
with structural features, which allow binding to one of the known 
cannabinoid receptors. Many of the substances in this structurally 
diverse group were initially designed for pharmacological research 
as potential pharmaceuticals to mimic the effects of cannabis. 
However, none are currently licensed for medical use.
2. Synthetic Cannabinoid 
Receptor Agonists
SCRAs on herbal material with packaging
10 
In the mid 2000s products containing SCRAs appeared in which the substances were 
added to plant material to mimic the herbal nature of cannabis. These products are 
sold as smokable “herbal blends” and “legal highs” under a variety of brand names 
such as “Spice”, “K2”, “Kronic” and are labelled as “not for human consumption”. 
SCRAs pose a considerable risk to health for a number of reasons. Many of the 
substances that appear in these products can be much more potent than THC. Also 
the content of products can vary both in terms of the actual substance or mixture of 
substances present and their concentration(s). As of October 2015, over 200 different 
SCRAs have been reported to UNODC.
Two SCRAs, namely JWH-018 (Naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone) and 
AM-2201 ([1-(5-fluoropentyl)-1H-indol-3-yl](naphthalen-1-yl)methanone), were placed 
under international control, following scheduling decisions of the 58th Commission  
on Narcotic Drugs (CND) in 2015 [2].
  Commonly  
used forms
  Route of  
administration
Herbal mixture, i.e. liquid solution of 
substance, dissolved in organic solvent 
and sprayed onto plant material
Inhalation (including vaporization)
White crystalline solid Oral consumption
Powder
• Nasal insufflation
• Oral consumption
Tablet Oral consumption
JWH-018
AM-2201
N
O
N
O
F
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2.1  MECHANISM OF ACTION AND 
RESULTING EFFECTS
JWH-018 and AM-2201 are both full agonists of the CB1 cannabinoid receptor. 
However, a lot of the pharmacological information, including the long-term effects 
of these substances is still unknown. Studies of potency in humans do not exist 
and users do not know what they are consuming, often leading to wrong doses 
and severe side effects due to overdose.
While the pharmacological effects are similar to those caused by THC, a number 
of additional effects, which are specific to SCRAs, are also listed below.
Undesired acute effects
• Seizures (convulsions), loss of 
consciousness
• Vomiting, drowsiness, chest pain
• Agitation, hot flushes 
• Dilation of pupils, dry mouth
Common street names*
JWH-018
Atomic Bomb
Chillin XXX
Dragon
K2
Monkees Go Bananas
Rockstar
Spice Head
Spike 99
Ultra
Wasted
AM-2201
Agent Orange
Atomic Bomb
Green
Jamaican Gold Extreme
Manga Xtreme
New Bonzai
XoXo
 *Note: Brand named products of SCRAs can 
differ from packet to packet, often contain 
substances other than those advertised, and 
can include multiple substances. 
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Opium and opiates3.
“Opium” means the coagulated juice of the opium poppy, where “opium 
poppy” means the plant of the species Papaver somniferum L. [2]. 
Papaver somniferum L. is a plant that grows in many countries around 
the world with moderate climates. It has white to red flowers and round 
to elongated capsules containing seeds which can range in colour from 
white to dark violet.
Opium poppies 
14 
There are a number of psychoactive substances that can be extracted from opium, 
with morphine and codeine being the most predominant.
MAJOR ALKALOIDS 
Percentage
Morphine  3.1 – 19.2
Codeine  0.7 – 6.6
Thebaine  0.2 – 10.6
Papaverine < 0.1 – 9.0
Noscapine  1.4 – 15.8
Opium seeds 
Morphine
Codeine
HO
HO
O
N
O
HO
O
N
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3.1 OPIUM PRODUCTS
Raw opium
Raw opium is a non-homogeneous material containing poppy capsule fragments. It is 
sticky, tar-like and dark brown when fresh, and becomes brittle and hard as it ages. 
Raw opium is produced by the air drying of opium.
  Commonly  
used forms
  Route of  
administration
Sticky or hard, dark brown material in 
any form or shape
• Oral consumption (chewed)
• Inhalation 
Blocks wrapped in vegetable leaves 
followed by plastic wrapping
Oral consumption (chewed)
Production
Raw opium is harvested from the seed capsule of the poppy, while the capsule is still 
in the green stage. The opium latex is obtained by making a series of shallow incisions 
into the capsule, which allows the latex to run onto its surface and be collected.
Prepared opium
Prepared opium is a sticky dark product obtained as a result of various treatments of 
raw opium, e.g. water extraction, in order to make it suitable for smoking.
  Commonly  
used forms
  Route of  
administration
Sticky or hard, dark brown material in 
any form or shape
Inhalation 
Sticks in the form of cigarettes Inhalation 
Common street names
Ah-pen-yen Noir(e)
Black Stuff O
Hop Tar
Mud
16 
Medicinal opium 
“Medicinal opium” means opium which has undergone the processes necessary to 
adapt it for medicinal use [2].
Common forms
Light yellowish-brown powder consisting of yellowish or reddish-brown particles.
Approved medical preparations of opium
Tincture
Fine brown powder
Pastilles
Syrup
Poppy straw
“Poppy straw” means all parts (except the seeds) of the opium poppy, after 
mowing  [2], which includes the dried upper part of the stem and the capsules  
of the poppy plant.
Concentrate of poppy straw 
The material arising when poppy straw has entered into a process for the 
concentration of its alkaloids, when such material is made available in trade [2].
  Commonly  
used forms
  Route of  
administration
Brown or off-white powder [7] Oral consumption
Common street names
Chandu
Sukhteh
Prepared opium
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3.2 OPIATES
Opiates are naturally occurring alkaloids of the opium poppy (Papaver somniferum L.), 
such as morphine, codeine, thebaine, etc. The term is often used interchangeably with 
opioids. However, opioids are synthetic compounds, which are derived from opiates 
but are not opiates themselves (see section 4). Opium, concentrate of poppy straw, 
morphine and heroin are under Schedule I of the Single Convention on Narcotic Drugs 
of 1961.
Morphine
Morphine is the most prevalent alkaloid extracted from opium or poppy straw. Its 
colour ranges from off-white to dark brown. Morphine can be found compressed into 
blocks with a variety of trademarks or names.
  Commonly  
used forms
  Route of  
administration
Finely ground powder Injection
Tablets Oral consumption
Heroin
Heroin (diamorphine or diacetylmorphine) is a semi-synthetic opiate synthesized from 
morphine. There are two main types, namely the water soluble diacetylmorphine 
hydrochloride salt and the relatively water insoluble diacetylmorphine base and both 
can appear in a range of colours from white to brown.
Following injection, heroin is rapidly broken down in the blood to the 
pharmacologically active 6-monoacetylmorphine and then to morphine, the major 
active metabolite. 
Compared to morphine, heroin is more fat-soluble (due to its two acetyl groups), and 
crosses the blood-brain barrier more rapidly, usually in 15-20 seconds, and achieves 
relatively higher levels in the brain following intravenous injection, with almost 70 per 
cent of the dose absorbed into the brain. Oral administration of heroin results in 
Heroin
O
O
O
N
O
O
18 
extensive breakdown to morphine [8]. Heroin is approximately twice as potent as 
morphine and has a high potential for abuse.
There are four regions in the world that have reported the production of heroin, 
namely South-West Asia, South-East Asia, Central America and South America. As such 
there are a variety of names that are used to designate the heroin in its various stages 
of refinement/purification which depend on the complexity of the processes used. 
These can include, for example, brown heroin and black tar heroin. In South-East Asia 
for example, heroin can be distinguished into several classes and the following terms 
are used:
  Commonly used forms
Heroin No. 2 Heroin base prior to its conversion to the hydrochloric salt: 
white to off-white, pale grey or dark brown, solid or powdered.
Heroin No. 3 Smokable form of heroin. Hard granular material ranging from 
light brown to dark grey, red or pink at times. Heroin No. 3 can 
be 20-40 per cent pure, although it is often lower e.g. less 
than 10 per cent and containing adulterants such as caffeine.
Heroin No. 4 Injectable form of heroin. It is a white powder, with little 
odour. Purity is high and may reach up to 99 per cent heroin 
hydrochloride (however, street purity is variable depending on 
adulterants added).
The main methods for the use of heroin are injection, nasal insufflation and 
inhalation by smoking.
Common street names
Black tar
Boy
Chiva
Dope
Dragon
H
Hairy
Harry
Horse
Joy powder
Junk
Skag
Smack
Snow
White lady
White stuff
Heroin No.3
RISKS OF INJECTION DRUG USE
Injecting drug use can lead to a number of severe infectious 
diseases. In particular, the sharing of needles or any other 
injection tools and injection using non-sterile and 
contaminated apparatus can transmit blood borne viral 
infections, such as HIV and/or hepatitis, pneumonia and 
other lung infections, and lead to cardiovascular issues.
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Medical use
Opium and opiates are still widely used in medicine to relieve symptoms of a variety 
of ailments. Morphine, for example, is used as an analgesic in cases of chronic pain 
management and for post-operative pain, while codeine is also used to treat a cough 
and mild to moderate pain. In some countries, heroin is also prescribed for pain 
management [9].
Mechanism of action and resulting effects  
(opium, morphine, heroin)
The pharmacological effects of morphine, heroin and other opiates are mediated 
through their interaction with opioid receptors and inhibitory neurotransmitters. Opioid 
receptors are responsible for triggering brain reward systems and producing analgesia 
(pain relief) by decreasing pain transmission. Different types of opioid receptors exist, 
among them are mu (µ) receptors, which mediate analgesic and behavioural effects.
Desired effects Undesired acute effects Effects of chronic use
• Sense of well-being 
and euphoria
• Warmth, 
contentment, 
relaxed detachment 
from emotional and 
physical distress
• Analgesia (pain 
relief)
• Drowsiness, inability to 
concentrate, apathy, 
lessened physical activity
• Potential nausea and 
vomiting
• Possible respiratory 
depression, which may 
lead to death
• Potential stimulatory 
effects
• Constriction of pupils
• Rapid development of 
tolerance and physical and 
psychological dependence
• Damage of structures in nose 
if sniffed or snorted
• Respiratory problems if 
smoked
• Malnutrition, weight loss
• Chronic sedation, apathy 
• Constipation 
• Menstrual irregularity
• Withdrawal syndrome (cramps, 
diarrhoea, runny nose, 
tremors, panic, fever, chills, 
uncontrollable shaking and 
sweating, etc.)
extraction
renement
renement
conversion
Raw opium 
(gum or latex)
Crude morphine
Morphine base
Heroin base
Heroin hydrochloride
Production of morphine 
and heroin*
*Poppy straw can be used as a source 
of crude morphine and codeine can 
be used to derive morphine base.
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Opioid is a generic term applied to opiates and their synthetic analogues, 
which can be semi- or fully synthetic, with actions similar to those of 
morphine. Therefore, opioids are commonly used as painkillers, for the 
treatment of acute and chronic pain, and as an anaesthetic during surgery. 
Synthetic opioids are structurally diverse, can be extremely potent, and 
include a variety of substances including a number of fentanyl derivatives, 
methadone, buprenorphine and AH-7921. 
4. Opioids
22 
4.1 FENTANYLS
Fentanyls are a group of short-acting, highly potent synthetic opioids with narcotic 
analgesic properties. Thirteen fentanyl compounds (acetyl-alpha-methylfentanyl, 
alfentanil, alpha-methylfentanyl, alpha-methylthiofentanyl, beta-hydroxyfentanyl, 
beta-hydroxy-3-methylfentanyl, fentanyl, 3-methylfentanyl, 3-methylthiofentanyl, 
para-fluorofentanyl, remifentanil, sufentanil and thiofentanyl) are under Schedule I of 
the Single Convention on Narcotic Drugs of 1961. Of these, four (alfentanil, fenantyl, 
remifentanil and sufentanil) are currently approved for medical use. There are however 
a range of fentanyls that are produced clandestinely. They are often sold mixed with 
heroin, and can have severe repercussions for users as a result of their high potency.
4.2 METHADONE AND BUPRENORPHINE
Methadone and buprenorphine are long-acting, commonly used synthetic opioid 
therapeutic drugs for detoxification or maintenance therapy in opioid dependence. 
Both methadone and buprenorphine are on the WHO Model Lists of Essential 
Medicines [10], and are used to treat dependence [11], for example, opioid substitution 
treatment or HIV prevention in people who inject drugs. 
4.3 AH-7921
AH-7921 is a synthetic opioid with analgesic opioid-like properties generally equipotent 
to morphine. Originally designed and investigated as a pharmaceutical opioid 
analgesic medicine, AH-7921 has not shown therapeutic applications and is  
not a licensed product.
Fentanyl
Methadone
Buprenorphine
N
O
N
O
N
O
N
H
O
OH
HO
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4.4  MECHANISM OF ACTION AND  
RESULTING EFFECTS
The effects of synthetic opioids are mediated through their interaction with inhibitory 
neurotransmitters and opioid receptors, as is the case for opium and opiates  
(see section 3.4).
Desired effects Undesired acute effects Effects of chronic use
• Euphoria
• Relaxation
• Analgesia 
(pain relief)
• Alertness
• Respiratory depression, 
sedation
• Nausea, vomiting
• Dizziness, fatigue, headache 
• Drowsiness, constipation, 
sweating 
• Anaemia, peripheral oedema
• Muscle rigidity
• Development of dependence 
and tolerance 
• Potential cardiac arrest or 
severe anaphylactic reaction 
• Withdrawal symptoms 
(sweating, anxiety, diarrhoea, 
bone pain, abdominal cramps, 
shivers or “goose flesh”)
• Constipation
Common street names
Fentanyls
Apache
China white
Drop dead
Synthetic heroin
Methadone
Chocolate-Chip Cookies
Dollies
Meth
Wafers
AH-7921 
Doxylam
Doxylan
Buprenorphine
Bupe
Subs
Tems
AH-7921
Cl
Cl
N
N
H
O
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5.1 COCA PRODUCTS
Coca bush
“Coca bush” means the plant of any species of the genus Erythroxylon [2].
The coca plant (e.g. Erythroxylon coca, Erythroxylon novogranatense)  
grows in tropical climates (500-2,500 metres above sea level) as a bush  
or tree. Its leaves can be harvested for about 20 years.
Coca leaf
“Coca leaf” means the leaf of the coca bush except leaf from which  
all ecgonine, cocaine and any other ecgonine alkaloids have been 
removed  [2]. This definition is specific to the Single Convention on  
Narcotic Drugs of 1961.
5. Coca and Cocaine
Cocaine
O O
O
O
NH3C
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  Commonly  
used forms
  Route of  
administration
Green to yellow-greenish elliptical leaves 
of different Erythroxylon species varying 
in size and appearance. The two lines 
parallel to the midrib on the underside 
of the coca leaf are distinctive.
Oral consumption. Coca leaf is chewed in 
combination with an alkaline compound (such 
as bicarbonate or plant ash to assist extraction 
of the alkaloids) or is brewed as a tea named 
“mate de coca”.
Chemical constituents of coca
MAIN ALKALOIDS 
Cocaine (benzoylmethylecgonine)
Cinnamoylcocaine 
Benzoylecgonine
Methylecgonine
Ecgonine
The amounts of the different alkaloids present in coca leaves depend on a number of 
factors, including the species, altitude at which the plant is grown, and age. The main 
psychoactive substance present in coca leaves is cocaine (benzoylmethylecgonine), 
which is generally present in the range of 0.3-1 per cent.
Coca paste
Coca paste is a crude extraction of the leaves of the coca bush. It contains coca 
alkaloids, 50-85 per cent cocaine and toxic impurities, such as sulphuric acid.  
Coca paste often contains aggregates, is damp and has a characteristic odour. 
  Commonly  
used forms
  Route of  
administration
Brown adhesive material to an off-white 
creamy or beige coarse powder
Inhalation either alone or mixed 
with tobacco
Common street names
Basuco
Bazuco
Pasta base
Paco
Coca plant
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Street names for coca paste vary depending on the country of production and the 
form. A particular street name for coca paste can also refer to different products in 
different countries.
Cocaine
Cocaine is the main psychoactive alkaloid obtained from coca leaves. It is generally 
encountered in two forms which differ in their route of administration. Cocaine 
hydrochloride, which is insufflated or injected, and cocaine base, which is a smokable 
form.
Crack and freebase are terms used for different forms of cocaine base generated from 
purified cocaine hydrochloride through specific conversion processes to make them 
suitable for smoking. Inhalation of the heated vapours of cocaine base results in a 
quick onset of effects due to the rapid absorption of the substances in the lungs. 
However, inhalation of cocaine pyrolysis products can be toxic and cause respiratory 
problems.
  Commonly  
used forms
  Route of  
administration
Cocaine base White or off-white 
crystalline powder with a 
characteristic odour
Inhalation 
Crack Hard white rocks Inhalation
Cocaine 
hydrochloride
White or off-white 
crystalline powder
• Nasal insufflation 
• Injection (intravenous or 
subcutaneous, “skin popping”, 
however, this is rare)
Cocaine, coca leaf, and ecgonine (including its esters and derivatives, which are 
convertible to ecgonine and cocaine) are under Schedule I of the Single Convention  
on Narcotic Drugs of 1961.
The following diagram shows the general processes by which coca leaf is transformed 
into cocaine products in their various forms. The illicit production processes may vary 
Common street names
Bazooka Coco Mister Coffee
Big C Coke Nose candy
Blanche Crack Shake
Blow Dust Snow
Cake Flake Star dust
Cane Koks Toot
Charlie Lady White lady
Crack
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from one laboratory to another; there are at least five reported methods for obtaining 
coca paste, cocaine base or cocaine hydrochloride. Illicit supplies of cocaine are often 
heavily adulterated with a variety of “cutting agents” and may contain as little as 10 
per cent cocaine. 
Production of cocaine
extraction
refinement
purification
purification
COCA LEAF
Cocaine content
COCAINE PASTE
COCAINE BASE
FREEBASE CRACK
COCAINE HYDROCHLORIDE
0.3–1%
50–85%
60–90%
60–90%
75–95% *
 *Note: Street purity can be much lower
Medical use
Cocaine hydrochloride solutions offer limited use as a local anaesthetic, except in 
certain cases of ear, nasal or throat surgery [12]. More effective and less harmful 
alternatives, such as benzocaine, lidocaine, prilocaine or combinations of these 
substances, are more commonly used in medical practice [13].
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Mechanism of action and resulting effects
The stimulatory properties of cocaine use are a result of its action on the dopamine, 
norepinephrine and serotonin neurotransmitter systems. To a certain extent, the 
effects of cocaine are similar to those of amphetamine and methamphetamine. 
However, cocaine has a more pronounced effect on the levels of dopamine than 
amphetamine or methamphetamine.
Desired effects Undesired acute effects Effects of chronic use
• Sense of physical and 
mental well-being, 
exhilaration, euphoria
• Increased alertness and 
energy
• Suppression of hunger
• Increased heart rate and 
blood pressure, faster 
breathing
• Increased body 
temperature, sweating
• Vasoconstriction, local 
anaesthesia
• Hyper-excitability, 
insomnia, restlessness, 
panic, erratic, sometimes 
violent behaviour. 
• May lead to convulsions, 
seizures, hallucinations, 
stroke, cerebral 
haemorrhage or heart 
failure
• Dysphoria, tiredness, 
irritability and depression
• Serotonergic syndrome
• Dilation of pupils
• Strong psychological 
dependence
• Development of 
tolerance
• Destruction of tissues  
in nose if insufflated
• Chronic bronchitis if 
smoked
• Malnutrition, weight 
loss
• Disorientation, apathy, 
confusion, exhaustion 
due to lack of sleep
• Paranoid psychosis
• During withdrawal there 
may be a long period of 
sleep and depression
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Amphetamine-type stimulants (ATS)5 refer to a group of drugs, mostly synthetic  
in origin, whose principal members include amphetamine, methamphetamine  
and MDMA (ecstasy). Use of these substances has a stimulatory effect on the 
central nervous system and influences the levels and action of the important 
neurotransmitters: dopamine, norepinephrine and serotonin. The action of these 
neurotransmitters induces a range of excitatory responses in the central nervous 
5The term “amphetamine-type stimulants” (ATS) was coined during the WHO Meeting on Ampheta-
mines, MDMA and other Psychostimulants in Geneva, 1996 [14]. This term was adopted by the meeting 
participants for the purpose of grouping a number of drugs that were prominent at the time, namely ampheta-
mine, methamphetamine and MDMA (ecstasy), among others. Moreover, it excluded cocaine, nicotine and 
certain herbal stimulants. A pragmatic justification was established to simplify the overarching class to a group 
of substances that are similar in their pharmacological effect and chemical structure. This grouping therefore 
incorporated substances, which were more or less structurally alike. 
6. Amphetamine-type 
Stimulants
3
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system. The differing degrees to which a substance affects these neurotransmitters 
contributes to the psychostimulant properties of individual ATS. There are also a 
number of synthetic stimulants that bear little structural similarity to ATS but have 
comparable mechanisms of action.
Amphetamine powder 
Yaba tablets containing methamphetamine
EXCITATORY NEUROTRANSMITTER SYSTEMS
The three monoamine neurotransmitters—dopamine, norepinephrine  
and serotonin—are critical components of neurotransmission. These 
neurotransmitters are released into neuronal synapses and their 
concentrations are modulated by membrane proteins.
The presence and/or levels of these three neurotransmitters produce  
a variety of effects as displayed in the table below.
Dopamine (DA) Norepinephrine (NE) Serotonin (5-HT)
Controls the reward 
and pleasure centre  
of the brain
Affects parts of the 
brain where attention 
and responding 
actions are controlled
Affects a variety of 
physiological 
processes, ranging 
from mood to appetite 
and memory
There are a number of overlapping effects, and the complexity of their 
relationship is illustrated below.
Norepinephrine Dopamine
Alertness
Concentration
Energy
Fight or flight
Stimulation
Serotonin
Reward
Pleasure
Motivation
Drive
Mood
Cognitive 
function
Memory
Compulsion
Anxiety
Impulse
Irritability
Aggression
Appetite
Sex
Attention
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6.1 AMPHETAMINE AND METHAMPHETAMINE
Amphetamine and methamphetamine produce predominantly stimulant effects 
as a result of their influence on the levels of dopamine and norepinephrine, and, 
to a lesser extent, on serotonin. Both substances are under Schedule II of the 
Convention on Psychotropic Substances of 1971.
Amphetamine and methamphetamine found in illicit markets are predominantly 
produced in clandestine laboratories. This is primarily related to the ease of 
synthesis and the availability of a variety of precursors and methods that can be 
used for their manufacture.
  Commonly  
used forms
  Route of  
administration
White to light brown powder
• Nasal insufflation
• Smoking 
Solution of powder dissolved in 
distilled or saline water
Injection
Tablets and capsules (in 
different shapes and colours)
Oral consumption
Crystals (commonly 
methamphetamine)
• Nasal insufflation 
• Smoking
The different methods by which these forms can be administered impacts the 
onset and duration of action. For instance, insufflation causes quick absorption 
into the bloodstream through the mucosa and so enables a more rapid onset of 
effects than oral consumption. In general, only methamphetamine is commonly 
found in the crystal form.
Amphetamine
Methamphetamine
NH2
H
N
NH2
H
N
Methamphetine crystals
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Medical use
There are a number of products containing amphetamine or methamphetamine, which 
are approved for medical use and predominantly prescribed to treat attention deficit 
hyperactivity disorder (ADHD), for example, Adderall® (a mixture of the chiral d- and 
l- salts of amphetamine) or Desoxyn® (d-methamphetamine). Amphetamine is also 
used in the treatment of narcolepsy and as an appetite suppressant [15]. 
Mechanism of action and resulting effects
Amphetamine and methamphetamine affect neurotransmitters through a number  
of mechanisms, namely by inducing the release and preventing the reuptake of 
dopamine, norepinephrine and, to a lesser extent, serotonin. They also inhibit the 
metabolism of dopamine and norepinephrine. The combination of these processes 
produces the stimulant effects, such as increased energy, heart rate and blood 
pressure.
Desired effects Undesired acute effects Effects of chronic use
• Sense of physical and 
mental well-being, 
exhilaration
• Mental and physical 
stimulation
• Increased and 
prolonged alertness and 
energy 
• Improved performance 
at manual or intellectual 
tasks
• Suppression of hunger 
• Increased heart rate and 
blood pressure, faster 
breathing
• Increased body 
temperature, sweating
• Erratic, sometimes 
violent behaviour
• Hyper-excitability, 
insomnia, talkativeness, 
restlessness, irritability, 
hallucinations
• Convulsions, seizures, 
arrhythmia and/or heart 
failure, cerebral 
haemorrhage
• Serotonergic syndrome
• Dilation of pupils
• Strong psychological 
dependence
• Development of tolerance
• Malnutrition, weight loss
• Disorientation, apathy, 
confused exhaustion due 
to lack of sleep
• With continued use, a 
state similar to paranoid 
psychosis may develop 
(known as “amphetamine 
psychosis”)
• During withdrawal there 
may be a long period of 
sleep and depression
SEROTONERGIC OR  
SEROTONIN SYNDROME
Serotonergic syndrome is an 
extreme adverse drug reaction, 
which is caused by excessive use 
of serotonergic drugs (drugs 
which influence the serotonin 
system) and is potentially fatal. It 
results from serotonin toxicity, i.e. 
extremely high levels of serotonin 
in the central nervous system 
induced by serotonergic drugs. 
Serotonergic syndrome may 
induce psychosis, high blood 
pressure (hypertension), high 
body temperature (hyperthermia), 
uncontrollable muscle spasms 
(myoclonic crisis), tremors, 
seizures, release of myoglobin 
from muscles and blood clotting 
in vessels. If not treated immedi-
ately, it may lead to severe illness 
and potential death.
Common street names
Amphetamine Methamphetamine
Amp Black beauties
Base Chalk
Bennies Crank
Crystal Crystal
Dexies Crystal meth
Speed Glass
Sulph Go-ey
Uppers Ice
Whizz Meth
Shabu
Speed
Yaba
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6.2 “ECSTASY” GROUP SUBSTANCES
This group comprises synthetic substances such as MDMA (3,4-methylene-
dioxymethamphetamine) MDA (3,4-methylenedioxyamphetamine) and MDEA 
(3,4-methylenedioxyethylamphetamine).
Similarly to amphetamine and methamphetamine, these substances have stimulant 
properties and affect, to varying degrees, the levels of the three neurotransmitters 
dopamine, norepinephrine and serotonin. However, the more pronounced effect on  
the serotonin neurotransmitter system leads to some differences in their overall 
pharmacological effects and is likely to be responsible for the empathogenic/
entactogenic effects of “ecstasy” group substances [16, 17].
The aforementioned “ecstasy” group substances are produced in clandestine 
laboratories, have no approved medical use, and are under Schedule I of the 
Convention on Psychotropic Substances of 1971. 
  Commonly  
used forms
  Route of  
administration
White to off-white powders
• Occasionally insufflation
• Injection (rarely)
Tablets and capsules Oral consumption
Mechanism of action and resulting effects
In addition to producing stimulant effects similar to those of amphetamine and 
methamphetamine, “ecstasy” group substances, to varying degrees, have more 
pronounced effects on inhibition of serotonin reuptake and can also exhibit binding 
affinity for serotonin receptors, which is likely to be responsible for its empathogenic/
entactogenic effects and potentially related to hallucinogenic effects at higher doses.
MDMA
MDA
MDEA
H
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O
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Common street names
Adam MDMA
E Molly
Ecstasy XTC
Essence Eve
Love drug MDE
MDM MDEA
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Desired effects Undesired acute effects Effects of chronic use
• Feelings of emotional 
closeness to others 
(empathy)
• Facilitation of 
communication 
• Increased sociability  
(use at so-called “rave” 
dance parties)
• Increased physical and 
emotional energy
• Rise in blood pressure 
and heart rate, heat 
stroke 
• Fatigue and potential 
depression 
• Restlessness, anxiety 
and pronounced visual 
and auditory 
hallucinations at high 
doses
• Nausea and vomiting
• Hyperthermia
• Serotonergic syndrome
• Development of tolerance
• Possibility of 
neurotoxicity, psychiatric 
and physical problems 
and brain damage as 
well as liver damage
• Potential depression, 
anxiety, fatigue, and 
difficulty in concentrating
“Ecstasy” tablets
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6.3 SYNTHETIC CATHINONES
Synthetic cathinones are beta-keto phenenthylamines that are similar to amphetamine, 
methamphetamine and MDMA in structure and mechanism of action. A number of 
synthetic cathinones are under international control including mephedrone, 
methylenedioxypyrovalerone (MDPV) and methylone. None of these substances are 
currently approved for medical use.
  Commonly  
used forms
  Mechanism  
of action
MPDV • Powder 
• Tablet
• Similar to amphetamine 
and methamphetamine
• Stimulant properties
Mephedrone • Powder
• Tablet
• Liquid (for injection)
• Similar to amphetamine 
and methamphetamine
• Stimulant properties
Methylone • Powder
• Tablet
• Liquid (for injection)
• Similar to MDMA
• Stimulant and 
entactogenic properties
MDPV
Mephedrone
Methylone
Common street names
Bath salt Mdmcat
Bk-MDMA Mef
Cristal bath Meow
Ease Neocor
Explosion New Ivory Wave
Flower Power Plant food
M1 Special
Magic Super coke
MP
O
NO
O
H
N
O
O
H
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O
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6.4 OTHER SYNTHETIC CNS STIMULANTS
There are a range of synthetic stimulants that can produce comparable effects 
to amphetamine, methamphetamine or “ecstasy” group substances but are not 
necessarily structurally similar. Some examples of substances in this category 
include 1-benzylpiperazine (BZP), aminorex, para-methoxyamfetamine (PMA) and 
3,4,5-trimethoxyamfetamine (TMA).
PMA
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Central nervous system (CNS) depressants are primarily 
used as medicines that suppress, inhibit or decrease brain 
activity. The main classes of CNS depressants are sedatives, 
hypnotics, opioids and neuroleptics [18]. CNS depressants 
include benzodiazepines, barbiturates, methaqualone and 
GHB (gamma-hydroxybutyric acid). 
7. Central Nervous System 
Depressants
Diazepam
N
N
O
Cl
Flunitrazepam
N
N
O
N
FO
O
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gamma(γ)-AMINOBUTYRIC 
ACID (GABA)
gamma(γ)-aminobutyric acid 
(GABA) is an example of an 
inhibitory neurotransmitter,  
which is critical in mediating 
sedative and therapeutic effects. 
It is located in the brain and 
spinal cord and helps regulate 
brain activity by reducing 
neurotransmission, which slows 
down normal functions of the 
body and culminates in 
depressant effects.
Depressant effects can also  
result from blocking the action  
of excitatory neurotransmitters 
(e.g. glutamate that acts on 
glutamate receptors [AMPA or 
NMDA]), which interrupts their 
main functionality of producing 
stimulatory effects and thus 
contributes to the depressant 
effects.
7.1 BENZODIAZEPINES
Benzodiazepines are a structural group of CNS depressants that are widely used  
in medicine as anticonvulsants, anxiolytics, hypnotics, sedatives, skeletal muscle 
relaxants and tranquilizers. Numerous benzodiazepines have been synthesized for 
use as pharmaceuticals and they can vary considerably in their potency and in the 
onset and/or duration of action. In total, 35 benzodiazepines are currently subject 
to international control under the Convention on Psychotropic Substances of 1971. 
Benzodiazepines encountered on the illicit market are primarily diverted from 
legitimate trade rather than synthesized in clandestine laboratories.
COMMON PHARMACEUTICAL 
BENZODIAZEPINES DURATION OF ACTION*
Alprazolam (Xanax®)  Short (half-life <10 hours)
Diazepam (Valium®) Long (>24 hours)
Chlordiazepoxide (Librium®) Long (>24 hours)
Flunitrazepam (Rohypnol®) Intermediate (10-24 hours)
Temazepam (Restoril®) Short (<10 hours)
  Commonly  
used forms
  Route of  
administration
Tablets and capsules Oral consumption
Liquids (gel) in capsules Injection
Mechanism of action and resulting effects
The depressant properties of benzodiazepines are derived from their effects on a 
combination of receptors in the GABAA receptor complex in the brain. Primarily, the 
benzodiazepines enhance the action of the neurotransmitter gamma-aminobutyric 
Common street names
Benzos
Blue bomb
Downers
Nerve pills
Canasson rouge
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acid (GABA) at the GABAA receptor to produce their sedative, hypnotic, anxiolytic, 
anticonvulsant and muscle relaxant effects. 
Desired effects Undesired acute effects Effects of chronic use
• Relief of tension, mental 
stress and anxiety
• Positive feelings of 
calmness, relaxation 
and well-being in 
anxious individuals
• Improved coping with 
situational pressures or 
psychological problems
• Relief of side effects 
associated with 
over-stimulation or 
withdrawal of other 
drugs (i.e. as part of  
a pattern of multiple 
drug use)
• Reduced mental activity 
and alertness, 
drowsiness, lethargy and 
impairment of clarity of 
thought and judgement 
may occur
• Potential impairment of 
muscle coordination, 
dizziness, low blood 
pressure, or fainting
• Diminished emotional 
responses to external 
stimuli, e.g. pain
• Development of 
tolerance, psychological 
and physical 
dependence 
• Headache, irritability, 
confusion, memory 
impairment, depression, 
insomnia and tremor
• Abrupt cessation may 
lead to withdrawal 
syndrome which can 
include insomnia, 
anxiety, perceptual 
hypersensitivity, tremors, 
irritability, nausea and 
vomiting, and even 
mental confusion and 
life-threatening 
convulsions
7.2 BARBITURATES
The barbiturates represent another group of synthetic CNS depressant drugs that 
were once widely used medically as hypnotics and sedatives. Their medical use 
today is limited to anti-epileptics or adjuncts to anaesthesia in surgical procedures 
and less commonly as anti-anxiety drugs. As with benzodiazepines, individual 
barbiturate drugs differ in the onset and duration of action and potency. Barbiturates 
have a low therapeutic index (a comparison of the amount which produces the 
therapeutic effect and that which results in toxicity) and overdosing can therefore be 
fatal. As a result, they have been largely replaced on both the licit and illicit market 
by the benzodiazepines. 
Phenobarbital
Amobarbital
HN
HN
O
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O
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Currently, twelve barbiturates are subject to international control under different 
schedules of the Convention on Psychotropic Substances of 1971. Secobarbital is under 
Schedule II, amobarbital, butalbital, cyclobarbital and pentobarbital are under 
Schedule III, and the remaining barbiturates (e.g. allobarbital, barbital, butobarbital, 
methylphenobarbital, phenobarbital, secbutabarbital and vinylbital) are under 
Schedule IV. 
COMMON PHARMACEUTICAL 
BARBITURATES
DURATION  
OF ACTION
Amobarbital (Amytal®) Intermediate (10-24 hours)
Pentobarbital (Nembutal®) Short (<10 hours)
Phenobarbital (Luminal®) Long (>24 hours)
Secobarbital (Seconal®) Short (<10 hours)
  Commonly  
used forms
  Route of  
administration
White powders Oral consumption
Capsules or tablets Oral consumption
Liquid pharmaceutical 
preparations
Injection
Suppositories Rectal
Mechanism of action and resulting effects
The depressant properties of barbiturates, from mild sedation to general anaesthesia, 
are derived from their activation of receptors in the GABAA receptor complex in the 
brain. Similarly to benzodiazepines, barbiturates enhance the action of GABA to 
produce their therapeutic effects.
Common street names
Barbiturates  
in general Amobarbital 
Barbitos
Barbs
Candy
Downers
Goofballs
Peanuts
Sleepers
Sleeping pills
Double trouble
Rainbows
Reds and blues
Pentobarbital Secobarbital
Nimbies
Yellow jackets
Pinks
Red birds
Red devils
Reds
Seggy
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Desired effects Undesired acute effects Effects of chronic use
• Relief of tension, mental 
stress and anxiety
• Positive feelings of 
pleasure, calmness, 
relaxation and sociability
• Improved coping with 
situational pressures or 
psychological problems
• Respiratory depression, 
weak and rapid heart 
rate, suppression of 
cough reflex
• Drowsiness, potential 
stupor, unconsciousness, 
coma
• Extreme, unpredictable 
emotional reactions and 
mental confusion, 
disorientation
• Slurred speech, poor 
control of speech, 
impaired judgement
• Loss of motor 
coordination, clumsiness, 
decreased self-control
• Dilation of pupils
• Development of 
tolerance, strong physical 
and psychological 
dependence
• Severe depression and 
amnesia 
• Bronchitis, pneumonia 
• Withdrawal may lead to 
irritability, nervousness, 
progressive restlessness, 
temporary sleep 
disturbances, faintness 
and nausea, anxiety, 
tremors, possible 
delirium and convulsions
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7.3 OTHER CNS DEPRESSANTS
Methaqualone
Methaqualone is a synthetic central nervous system (CNS) depressant with sedative-
hypnotic, anticonvulsant, antispasmodic and local anaesthetic properties. It was 
withdrawn from the pharmaceutical market in many countries as a result of 
problems of abuse.
Methaqualone is under Schedule II of the Convention on Psychotropic Substances 
of 1971.
  Commonly  
used forms
  Route of  
administration
Brown, grey or black tacky powder Nasal insufflation
Tablets or capsules Oral consumption
Mechanism of action and resulting effects
The sedative and hypnotic properties of methaqualone are mediated through its 
effect on GABA receptors in a similar manner to other CNS depressants.
Desired effects Undesired acute effects and effects of chronic use
• Relief of tension, mental 
stress and anxiety
• Relief of side effects 
associated with over-
stimulation or withdrawal 
of other drugs (i.e. as part 
of a pattern of multiple 
drug use)
Similar to those of other CNS depressants, including 
reduction of mental activity, cardiac and respiratory 
depression as well as the development of tolerance,  
and psychological and physical dependence
Common street names 
714s Ludes
Quaalude Mandrax
Lemons Parest
Methaqualone
N
N
O
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gamma (γ)-hydroxybutyric acid (GHB)
GHB is a CNS depressant, which produces sedation and anaesthesia and is associated 
with drug-facilitated sexual assault. It is under Schedule II of the Convention on 
Psychotropic Substances of 1971. 
GHB can be manufactured clandestinely from inexpensive ingredients and methods 
found on the Internet. It is also generated in the body after ingestion of the solvents 
gamma-butyrolactone (GBL) or 1,4-butanediol.
Medical use
Medically, GHB has been used as an adjunct in anaesthesia and as an aid to alcohol 
or opiate withdrawal. In addition, GHB (e.g. Xyrem®) has been used to treat insomnia 
and clinical depression [19].
  Commonly  
used forms
  Route of  
administration
Clear liquid (substance dissolved in water)
• Oral consumption
• Injection
• White powder (as a salt)
• Tablets or capsules
Oral consumption
Mechanism of action and resulting effects
The effects of GHB are mediated through its activation of a specific GHB receptor, 
which is excitatory, and its activation of the GABAB receptor, which has inhibitory 
properties. GHB has also been shown to affect the dopamine neurotransmitter system.
Desired effects Undesired acute effects and effects of chronic use
• Similar to other CNS 
depressants: relaxation, 
reduced inhibition, euphoria 
and mild hallucinations
• Promotes growth hormone 
effects of alleged stimulation 
of muscle growth 
• Similar to those of other CNS depressants, including 
the development of psychological and physical 
dependence, and a withdrawal syndrome after 
discontinuation of prolonged use of large doses
• Potential blackouts
• In conjunction with other CNS depressants, adverse 
effects are exacerbated
Common street names
Cherry meth GHB
Cloud-9 Liquid E
Fantasy Liquid Ecstasy
G Liquid X
Goop Sleep
Georgia Home Boy Scoop
GHB
O
OH
HO
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Hallucinogens are a diverse group of naturally occurring and synthetic drugs  
that induce distorted states of consciousness, perception, thinking and feeling, 
accompanied by different degrees of auditory or visual hallucinations. They are 
also referred to as “psychedelics”, which ultimately produce synaesthesia6 [20] 
and altered perceptions of reality. 
Hallucinogens fall into several chemically related groups, including tryptamine 
(e.g., (+)-lysergide [LSD] and psilocin), and phenethylamine (e.g., mescaline and 
25B-NBOMe).
6Synaesthesia is an extraordinary condition in which senses that are usually experienced separately 
are combined, so that a person hearing a sound may see a colour as a result (e.g. hearing colours).
8. Hallucinogens
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8.1 (+)–LYSERGIDE (LSD)
LSD is a semi-synthetic drug derived from lysergic acid, an alkaloid found in a fungus, 
Claviceps purpurea, which grows on rye and other grains. LSD is one of the most 
potent hallucinogenic substances known and is listed in Schedule I of the Convention 
on Psychotropic Substances of 1971. 
  Commonly  
used forms
  Route of  
administration
• Impregnated on paper (blotter 
papers)
• Mini tablets (“microdots”) and 
capsules
• Thin gelatine sheets (“window 
panes”)
Oral consumption
Mechanism of action and resulting effects
LSD has a complex pharmacology and its mechanism of action is not completely 
understood. It has affinity for a number of serotonin receptors and its hallucinogenic 
effects have been linked to its agonist activity at the 5-HT2A receptor. LSD can have a 
duration of action as long as 10-12 hours [21].
The effects of LSD are extremely variable and strongly depend on the mental state of 
the user and the setting, i.e. the same dose in the same user may produce good and 
bad “trips”, depending on circumstances of use. Thus, the type of effects produced 
are subject to different confounding factors.
LSD
LSD tablets
N
NH
ON
H
H
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Desired effects Undesired acute effects Effects of chronic use
• Alterations in thought, 
mood and sensory 
perception, “mind 
expansion”
• Sense of empathy, 
facilitation of 
communication and 
increased sociability 
• Increased heart rate, 
profuse sweating
• Distorted perception  
of depth, time, size  
and shape of objects, 
movements of stationary 
objects, intensified 
colours, sound and 
touch
• Potential anxiety, 
depression, dizziness, 
disorientation and 
paranoia
• Dilation of pupils, 
decreased body 
temperature, nausea 
and vomiting
• Convulsions may occur
• Potential prolonged 
anxiety and depression
• Rapid development of 
tolerance
• “Flashbacks”  
(i.e. short-lived, vivid 
re-experiences of part  
of a previous trip) can 
occur days or even 
months after taking the 
last dose, leading to 
disorientation and 
distress
• Physical dangers 
attributable to long-term 
LSD use are not known
8.2 TRYPTAMINES
Hallucinogenic tryptamines are a group of substances, which are related to both LSD 
and psilocybin in their structure and action. Several tryptamines occur naturally in a 
variety of plants, fungi or animals, and have a history of use as hallucinogenic snuffs 
or drinks, for example, in the Amazon forest and the Caribbean. They can also be 
manufactured through chemical synthesis.
There are three tryptamines under international control: diethyltryptamine (DET), 
dimethyltryptamine (DMT) and etryptamine, which are in Schedule I of the Convention 
on Psychotropic Substances of 1971. Currently, no tryptamines are approved for 
medical use.
Common street names
Hippie
Acid
Blotter
Dimethyltryptamine
LSD tablets
N
H
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A peyote cactus
  Commonly  
used forms
  Route of  
administration
Dark brown solid material 
(crude plant preparation)
Inhalation
Powder Nasal insufflation
Oily liquid Injection
Tablets, capsules Oral consumption—if tryptamines are 
in tablet or capsule form. However, 
they are rarely consumed orally
Mechanism of action and resulting effects
Tryptamines share a similar mode of action to LSD and act as non-selective 
serotonin receptor agonists. The impairment of coordination following their use is 
frequently more pronounced than that produced by LSD. Their effects are very dose 
dependent, and their duration of action can be extremely short (a few minutes), 
particularly when smoked.
8.3 PLANT-BASED HALLUCINOGENS
Peyote cactus and mescaline
Mescaline is the main psychoactive component of the peyote cactus (Lophophora 
williamsii). The mescaline content in peyote varies depending on environmental 
factors (temperature, rainfall, altitude) and soil conditions and can range from 
0.7 –3.5 per cent of the dried weight. Mescaline can also be synthesized 
clandestinely and is under Schedule I of the Convention on Psychotropic 
Substances of 1971.
Mescaline
Common street names
Businessman’s LSD
Businessman’s lunch trip
O
O
O
NH2
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  Commonly  
used forms
  Route of  
administration
Dried, sliced and chopped in the 
form of a button (mescal button)
Oral consumption (chewed, or 
soaked in water to produce an 
intoxicating liquid)
Ground button of the cactus,  
in capsules
Oral consumption
Powder, in capsules or tablets Inhalation
Mechanism of action and resulting effects
The mechanism of action of mescaline is similar to other hallucinogens and its 
effects are mediated through its interaction with serotonin receptors (e.g. 5-HT2A ). 
Mescaline is less potent than LSD but its effects can last up to 10-12 hours. 
Desired effects Undesired acute effects
Alterations in thought, mood 
and sensory perception
• Unlike LSD, the effects of mescaline 
include euphoria, hilarity and 
prominent signs of physiological 
arousal, such as increased heart rate 
and blood pressure, dilation of 
pupils, nausea, vomiting and 
stomach pains.
• Euphoria and detachment from 
surroundings
• Visual distortions progress to vivid 
hallucinations of colour and 
movement
Common street names
Mescaline Mescal button
Big chief Buttons
Mesc Peyote
Moon Peyotl
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Psilocybe mushrooms and psilocybin 
Psilocybin is the naturally occurring, hallucinogenic substance primarily found in the 
Psilocybe mexicana mushroom although there are more than 75 species of mushrooms 
from the genera Psilocybe, Panaeolus and Conocybe that can contain psilocybin. The 
psilocybin content of Psilocybe mushrooms can vary from between 0.2–2 per cent [22]. 
 
  Commonly  
used forms
  Route of  
administration
Intact dried brown mushrooms • Oral consumption (swallowed 
raw, cooked, or brewed into a 
beverage)
• Intravenous injection (of 
extracts, occurs rarely)
Crude mushroom preparation
Powdered material in capsules
Mechanism of action and resulting effects
Following ingestion of mushrooms containing psilocybin, the psilocybin is converted 
into its more active metabolite psilocin, and the hallucinogenic effects are mediated 
through its action as a serotonin receptor agonist similar to other hallucinogens. The 
duration of action is typically 4–6 hours.
Desired effects Undesired acute effects
Alterations in thought, mood and 
sensory perception
• Physical effects include muscle 
weakness, drowsiness and lack of 
coordination 
• Fatal poisoning may occur due to 
mistaken identity of mushrooms
• Tolerance may develop
Psilocybin is under Schedule I of 
the Convention on Psychotropic 
Substances of 1971.
Dried psilocybin mushrooms
Psilocybin
P
OHO
HO O
N
H
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Common street names
Divine flesh Sacred mushrooms
Hombrecitos Shrooms
Magic mushrooms Teonanácatl
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8.4 SYNTHETIC HALLUCINOGENS
There are a number of synthetic substances which act in a similar way to the plant-
based hallucinogens. These substances are in general structurally similar to mescaline 
(a phenethylamine) and amphetamine/methamphetamine. Their predominant effects 
are hallucinatory, but some of the substances can also have stimulatory effects [23]. 
This group includes substances such as DOB (brolamfetamine), 2C-B and 25I-NBOMe. 
None of the substances in this group are approved for medical use.
Common substances
25I-NBOMe (2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine)
2C-B (4-bromo-2,5-dimethoxyphenethylamine)
DOB (Brolamfetamine)
STP/DOM (2,5-dimethoxy-4-methylamphetamine)
TMA (3,4,5-trimethoxyamphetamine)
2C-B is a phenethylamine with hallucinogenic properties [24] that became popular 
during the mid-1980s. 2C-B is in Schedule II of the Convention on Psychotropic 
Substances of 1971.
DOB is a highly potent phenethylamine with hallucinogenic effects. It was a popular 
drug of abuse in the 1980s with effects lasting longer than those of 2C-B. DOB is in 
Schedule I of the Convention on Psychotropic Substances of 1971.
The NBOMe series are a group of synthetic hallucinogens that are derivatives of  
the “2C series” of substances and are often sold as LSD. These substances vary in 
potency, pharmacological effects and toxicity, and as such errors in dosage may  
have fatal consequences [25]. As with LSD, NBOMe substances are commonly sold  
on blotter paper, yet in contrast to LSD, they are accompanied by a bitter taste. 
25B-NBOMe, 25C-NBOMe, and 25I-NBOMe, are in Schedule II of the Convention on 
Psychotropic Substances of 1971.
2C-B
DOB
25I-NBOMe
NH2O
OBr
NH2O
OBr
I
O
H
N
O
O
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  Commonly  
used forms
  Route of  
administration
DOB
White to off-white powders
• Nasal insufflation (occasionally)
• Injection (rarely)
Tablets and capsules Oral consumption
Impregnated on paper Oral consumption
2C-B
Powder Nasal insufflation
Tablet Oral consumption
25B-NBOMe, 25C-NBOMe, and 25I-NBOMe
Finely ground powder 
• Nasal insufflation
• Inhalation (vaporizer)
Tablet Oral consumption
Liquid 
• Intravenous and intramuscular injection
• Nasal insufflation (of liquid)
Blotter paper Oral consumption
Blotter into gel capsule or suppository Rectal
Mechanism of action and resulting effects
Synthetic hallucinogens have a similar pharmacological profile to that of LSD and 
other plant-based hallucinogenic substances. They act, to varying extents, at the  
5-HT2A receptor (e.g., 2C-B acts as a partial agonist, while 25I-NBOMe is a potent full 
agonist). The potency and duration of action of the individual substances depends on 
a number of factors including the chemical substituents present.
Common street names
DOB
STP: Serenity, Tranquillity, Peace
2C-B
Venus
Bromo
Erox
Bees
Nexus
25I-NBOMe
25I
BOM-25
BOMCI
Cimbi-5
Dots
Legal acid
N-boom
NBomb
NE-BOME
Smiles
Smiley paper
Solaris
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Desired effects Undesired acute effects Effects of chronic use
• Alterations in thought, 
mood and sensory 
perception Mental and 
physical stimulation
• Changes in body 
temperature (sweating  
or chills)
• Nausea, vomiting
• Muscle twitching, tension
• Confusion and difficulty 
focusing
• Insomnia
• Paranoia, fear and panic
• Unpleasant visions, 
unwanted and 
overwhelming feelings
• Visual and auditory 
hallucinations
• Dilation of pupils 
• General change in 
consciousness
• Unusual body sensations 
(facial flushing, chills, 
goose bumps, body 
energy) 
• Slight increase in heart 
rate
• Vasoconstriction, 
peripheral numbness, 
swelling of feet, hands  
or face 
• Change in perception of 
time, time dilation
• Looping, recursive out of 
control thinking
• Scrambled 
communication
• Unwanted life-changing 
spiritual experiences
• Risk of neurological 
damage, such as 
progressive 
encephalopathy and 
muscle weakness in the 
limbs (“quadriparesis”)
• Increased heart rate, 
high blood pressure, 
exceptionally high fever
• Excessive acid in blood
• Seizures, involuntary, 
muscular contractions 
and relaxations in rapid 
succession
• Rapid destruction of 
muscle tissue 
• Acute kidney injury
• Potential violent, erratic 
behaviour, agitation and 
aggression
• Further effects are not  
yet known, but are 
potentially similar to 
those of LSD
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PCP
8.5 PHENCYCLIDINE (PCP)
Phencyclidine is a synthetic drug with anaesthetic and hallucinogenic properties. 
PCP was investigated in the 1950s for its anaesthetic potential, but was withdrawn 
from the pharmaceutical market due to its severe side effects. PCP is under 
Schedule II of the Single Convention on Narcotic Drugs of 1961.
  Commonly  
used forms
  Route of  
administration
White to grey or brown crystalline 
powder or gummy mass
Nasal insufflation
Tablets or capsules Oral consumption
Liquid
Inhalation—often applied to leafy 
material
Mechanism of action and resulting effects
PCP is a dissociative anaesthetic with hallucinogenic properties. In contrast to LSD, 
the hallucinogenic properties of PCP are a result of its action as an NMDA 
(N-methyl-D-aspartate) receptor antagonist. In addition, PCP has stimulant 
properties as it inhibits the reuptake of dopamine, norepinephrine and serotonin, 
thus intensifying the effect of these neurotransmitters.
Common street names
Angel dust
DOA (dead on arrival)
Hoy
Killer weed
Magic dust
Peace pills
Rocket fuel
Space basing (PCP with crack)
N
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Desired effects Undesired acute effects Effects of chronic use
• Alterations in thought, 
mood and sensory 
perception
• Out-of-body experiences
• Changes in body 
awareness, feelings of 
detachment and distance
• Loss of comprehension 
of the immediate 
environment, often 
accompanied by a sense 
of strength and 
invulnerability
• Hallucinations, image 
distortion, severe mood 
disorders, mental 
confusion, amnesia 
• Potential acute anxiety, 
paranoia and violent 
hostility, or 
schizophrenia-like 
psychoses 
• Numbness of the 
extremities, slurred 
speech and loss of 
coordination
• Shallow respiration, 
increased rate of 
breathing, blood 
pressure and heart rate, 
flushing and profuse 
sweating, blank stare, 
rapid and involuntary  
eye movements, watering 
of eyes
• Potential convulsions, 
coma
• Development of tolerance 
and strong psychological 
dependence
• “Flashbacks”  
(i.e. short-lived, vivid 
re-experiences of part  
of a previous trip) can 
occur days or even 
months after taking the 
last dose, leading to 
disorientation, anxiety 
and distress
• Impaired memory
• Speech difficulties  
(e.g. stuttering or the 
inability to speak)
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Most definitions are based on those given in the Lexicon of Alcohol and 
Drug Terms (Geneva, 1994) of the World Health Organization (WHO). 
These terms have been adapted where necessary and cross-references 
are provided in italics.
Glossary of Terms
60 
ABUSE Due to the ambiguity of the term “abuse”, the WHO Lexicon has replaced 
this term with “harmful use” and “hazardous use”, which is defined as 
follows:
Harmful use is a pattern of psychoactive substance use that is 
causing damage to health, physical (e.g. hepatitis following injection 
of drugs) or mental (e.g. depressive episodes secondary to heavy 
alcohol intake). Harmful use commonly, but not invariably, has 
adverse social consequences. The term was introduced in ICD-10 and 
supplanted “non-dependent use” as a diagnostic term.
Hazardous use is a pattern of substance use that increases the risk  
of harmful consequences for the user. In contrast to harmful use, 
hazardous use refers to patterns of use that are of public health 
significance despite the absence of any current disorder in the 
individual user.
In the context of international drug control, drug abuse constitutes  
the use of any substance under international control outside 
therapeutic indications, in excessive dose levels, or over an 
unjustified period of time.
ABUSE LIABILITY The propensity of a particular psychoactive substance to be susceptible  
to abuse, defined in terms of the relative probability that use of the 
substance will result in social, psychological and physical problems for  
an individual or for society.
ACUTE EFFECT Effects produced by a single dose or a short period of continuous 
administration of a drug.
ADDICTION The terms “addiction” and “habituation” were abandoned by WHO in  
1964 in favour of drug dependence. However, since those terms are  
still widely used, below is a definition of “addiction”.
“Addiction” refers to the repeated use of a psychoactive substance or 
substances, to the extent that the user is periodically or chronically 
intoxicated, shows a compulsion to take the preferred substance (or 
substances), has great difficulty in voluntarily ceasing or modifying 
substance use, and exhibits determination to obtain psychoactive 
substances by almost any means.
ADJUNCT An additional drug, substance or procedure that is used to strengthen  
or increase the efficacy of the initial treatment.
ADULTERANTS A substance that is added to a drug to increase the quantity produced, 
enhance the pharmacological and psychoactive effect, or facilitate the 
administration of the drug. Adulterants may include sugars, caffeine, 
lidocaine or paracetamol. However, other adulterants may be more 
harmful, particularly when administered through injection.
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ADVERSE DRUG 
REACTION
In the general medical and pharmacological fields, “adverse drug reaction” 
denotes a toxic physical or (less common) psychological reaction to a 
therapeutic agent. The reaction may be predictable, or allergic or 
idiosyncratic (unpredictable). In the context of drug abuse, the term 
includes unpleasant psychological and physical reactions to drug taking.
AGONIST A substance that acts at a neuronal receptor to produce effects similar  
to those of a reference drug. For example, methadone is a morphine-like 
agonist at the opioid receptors.
Full agonist is a substance that produces a full response or the 
maximum effect at a given receptor.
Partial agonist is a substance that produces a reduced response as  
it is unable to elicit the maximum effect or response.
ANALGESIC A substance that reduces pain and may or may not have psychoactive 
properties. 
ANTAGONIST A substance that counteracts the effects of another agent. 
Pharmacologically, an antagonist interacts with a receptor to inhibit  
the action of agents (agonists) that produce specific physiological or 
behavioural effects mediated by that receptor.
ANTIDEPRESSANT Any of a group of psychoactive agents prescribed for the treatment of 
depressive disorders; also used for certain other conditions such as  
panic disorder. There are three main classes: (a) tricyclic antidepressants, 
(b) serotonin receptor agonists and uptake blockers, and (c) monoamine 
oxidase inhibitors. None of the common antidepressants is under 
international control.
BLOOD-BRAIN  
BARRIER
A network of blood vessels that separates the brain from the circulatory 
system (blood) and acts as a protective layer of the central nervous  
system (CNS), restricting the passage of certain harmful substances,  
while enabling that of necessary substances. 
CENTRAL NERVOUS 
SYSTEM (CNS)
The CNS is a part of the nervous system, which comprises the brain and 
spinal cord, and is responsible for most functions of the body, including 
processes under voluntary and involuntary control. 
Functions range from breathing and blinking, which are involuntary 
processes, to speaking and walking, which are voluntary processes, and  
to emotions and perceptions. Within the CNS, the brain stores, processes 
and interprets sensory information and the spinal cord acts as the bridge 
between the brain and peripheral nerves by relaying signals to the rest  
of the body through the peripheral nervous system (PNS).
CHRONIC USE Prolonged, continuous, frequent, long-term or heavy use of a substance 
over a certain period of time, leading to severe adverse health effects. 
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INTERNATIONAL  
DRUG CONVENTIONS
The three main international drug conventions are:
Single Convention on Narcotic Drugs of 1961 as amended by the 1972 
Protocol establishes an international control system for narcotic drugs. 
Convention on Psychoactive Substances of 1971 establishes an 
international control system for psychotropic substances.
United Nations Convention against Illicit Traffic in Narcotic Drugs  
and Psychotropic Substances of 1988, which provides comprehensive 
measures against drug trafficking, including provisions against 
money-laundering and the diversion of precursor chemicals.
SUBSTANCES under 
INTERNATIONAL 
CONTROL
Refers to substances listed in the schedules (for the 1961 and 1971 
Conventions) and tables (for the 1988 Convention) which are annexed to 
these conventions.
(DRUG) DEPENDENCE The term was introduced in 1964 by a WHO Expert Committee to replace 
addiction and habituation.
“Drug dependence” comprises a cluster of physiological, behavioural  
and cognitive phenomena of variable intensity, in which the use of a 
psychoactive drug (or drugs) takes on a high priority. It implies a need  
for repeated doses of the drug and indicates that a person has impaired 
control of substance use, as its use is continued despite adverse 
consequences.
PSYCHOLOGICAL or PSYCHIC DEPENDENCE refers to the experience  
of impaired control over drug use.
PHYSIOLOGICAL or PHYSICAL DEPENDENCE involves the development 
of tolerance and withdrawal symptoms upon cessation of use of the 
drug, as a consequence of the body’s adaptation to the continued 
presence of a drug.
DOSE A dose is the quantity of a substance, which is required to elicit the 
desired response in the individual, both in medicine and for abuse 
purposes. This dose will vary depending on a number of factors, including 
the particular substance, its form, the route of administration, and the 
drug consumption history of the individual. Doses are therefore highly 
dependent on various effects, including past drug experiences, individual 
differences in weight and size and whether a drug is taken in combination 
with other substances (e.g. poly-drug use). Average doses are not 
generalizable or applicable to every person.
Differences in the purity, potency and concentration of substances has 
implications on dosages and the amount that is consumed by an 
individual. For example, substances with high potency may require small 
doses, to produce similar pharmacological effects. While some substances 
are effective in milligrams or grams, others may exert their effect with as 
little as a few micrograms (1 microgram is equal to 0.000001 grams).
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Additional confounding factors exist that make accurate ranges of  
dosing information equivocal. There is a lack of information about  
social behaviour and drug consumption patterns are highly variable,  
which in turn makes the level of use inexact. Data on average doses  
can therefore only provide certain estimates of use, which does not 
accurately reflect consumption patterns.
In certain cases, the “defined daily doses” used by the International 
Narcotics Control Board (INCB) for narcotic drugs and psychotropic 
substances, which is available in their technical reports, may provide 
further guidance.
Drugs or substances that are used repeatedly over time can lead to the 
development of tolerance. During tolerance the body does not respond  
to the substance at the same dosage and therefore, higher amounts of  
the substance are required to achieve the desired effect.
DRUG In the context of international drug control, “drug” means any of the 
substances in Schedule I and II of the 1961 Convention, whether natural  
or synthetic. 
A term of varied usage. In medicine, it refers to any substance with the 
potential to prevent or cure disease or enhance physical or mental welfare; 
in pharmacology it means any chemical agent that alters the biochemical 
or physiological processes of tissues or organisms.
DRUG TESTING The identification and chemical analysis of drugs in seized material and 
biological specimens, i.e. body fluids (urine, blood, saliva), hair, or other 
tissue, in order to assess the presence of one or more psychoactive 
substances.
ENTACTOGEN (or 
EMPATHOGEN)
Term derived from the Greek “en” (inside) and “gen” (to induce) and the 
Latin “tactus” (tact). It describes a condition that allows users to “make 
contact” with their own feelings and those of others. Examples of 
controlled drugs include MDMA (“ecstasy”).
HYPERTHERMIA An abnormally high body temperature.
HYPNOTIC Any of a group of central nervous system depressants with the capacity  
to induce sleep. Major classes of sedatives/hypnotics include the 
benzodiazepines and barbiturates. See also sedative.
ILLICIT TRAFFIC The manufacture, cultivation or trafficking in drugs or psychotropic 
substances contrary to the provisions of the Conventions.
LICIT DRUG A drug that is legally available by medical prescription in the jurisdiction  
in question, or, sometimes, a drug legally available without medical 
prescription.
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NARCOTIC DRUG In the context of international drug control, “narcotic drug” means any  
of the substances, natural or synthetic, in Schedules I and II of the  
Single Convention on Narcotic Drugs, 1961, and that Convention as 
amended by the 1972 Protocol Amending the Single Convention on Narcotic 
Drugs, 1961.
In medicine, a chemical agent that induces stupor, coma or insensibility  
to pain (also called narcotic analgesic). The term usually refers to opiates 
or opioids, which are also named narcotic analgesics. In common parlance 
and legal usage, it is often used imprecisely to mean illicit drugs, 
irrespective of their pharmacology. 
NEUROLEPTIC Any of a group of drugs used for the treatment of acute and chronic 
psychoses. Also known as major tranquillizers and antipsychotics. 
Neuroleptics have low abuse potential.
NEUROTRANSMITTER A chemical messenger that is endogenous to the body and transmits 
signals between neurons to enable a form of communication between 
individual cells or neurons in the body. Dopamine, norepinephrine  
(or noradrenaline) and serotonin are examples of neurotransmitters.
OVERDOSE The use of any drug in such an amount that acute adverse physical or 
mental effects are produced. Overdose may produce transient or lasting 
effects, or death; the lethal dose of a particular drug varies with the 
individual and with circumstances. See also: intoxication; poisoning.
PHARMACEUTICAL 
DRUGS
Drugs manufactured by the pharmaceutical industry or made up by a 
pharmacist. Industry terminology categorizes drugs as ethical drugs, 
available only on prescription, and over-the-counter or proprietary drugs, 
advertised to the consumer and sold without prescription. The list of  
drugs requiring prescription varies considerably from country to country; 
most psychoactive pharmaceuticals are only available by prescription in 
industrialized countries. 
PHARMACOLOGY “Pharmacology” is the science of drugs, including their sources, 
appearance, chemical composition, properties, biological actions and 
therapeutic uses. It also covers allied fields such as toxicology and 
posology (see definition below).
POSOLOGY “Posology” is the study of dosage and is an important division of 
pharmacology. Knowledge of the dose of commonly used drugs is  
essential for acquiring confidence in prescribing.
PSYCHEDELIC The distinct feature of “psychedelic” drugs is their capacity to induce 
states of altered perception, thought and feeling that are not experienced 
otherwise except in dreams or at times of religious exaltation; they can, 
but not necessarily, produce overt hallucinations.
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PSYCHOTROPIC or 
PSYCHOACTIVE 
SUBSTANCE
Any chemical agent affecting the mind or mental processes (i.e. any 
psychoactive drug). In the context of international drug control, 
“psychotropic substance” means any substance, natural or synthetic,  
or any natural material in Schedule I, II, III or IV of the 1971 Convention.
RECEPTOR A protein structure, embedded in cell membranes, which enables the 
binding and movement of substances such as drugs, hormones or 
neurotransmitters and thus is involved in conveying cellular signals. 
Receptors are named after the type of neurotransmitter that they 
preferentially bind to, for instance, dopamine receptors.
ROUTE of 
ADMINISTRATION
The way in which a substance is introduced into the body, such as oral 
ingestion, intravenous (IV), subcutaneous or intramuscular injection, 
inhalation, smoking, or absorption through skin or mucosal surfaces, 
such as the gums, rectum or genitalia. This process determines the rate 
at which a substance is absorbed into the bloodstream. The following are 
some common routes of administration described in this publication:
ORAL CONSUMPTION refers to the administration of the substance 
using the mouth. Tablets or capsules are swallowed and substances 
are ingested and broken down into metabolites through the 
digestive system. These forms pass the intestines and only once 
dissolved are they able to cross the mucosal membranes in order  
to reach the bloodstream, pass the blood brain barrier and produce 
effects. Given the length of time needed for these processes to 
occur, substances administered orally have a slower onset but have 
a longer duration of effects. There is a dose-dependent mechanism 
of some drugs, in which a higher dose results in a longer duration 
of effects, thus making it difficult to quantify precisely. 
Buccal refers to the placement of a substance into the mouth 
until it is dissolved.
Sublingual refers to the placement of a substance underneath 
the tongue until it is dissolved. 
INJECTION refers to the administration of a drug through the skin 
using a syringe or any other injection tools. This route poses a 
serious public health risk as infectious diseases such as HIV or 
hepatitis can be passed from person to person through the sharing 
of injection equipment. Three methods of injection exist, namely 
intramuscular, intravenous (IV) or subcutaneous injections.
Intramuscular is an injection through the muscle, which is the 
slowest method of drug delivery throughout the body.
Intravenous (IV) is an injection through the veins, and also the 
fastest distribution, as the drug is inserted directly into the 
bloodstream.
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ROUTE of 
ADMINISTRATION 
(continued)
Subcutaneous is an injection immediately under the skin,  
which is a relatively slow method of delivery.
NASAL INSUFFLATION refers to the consumption of a drug through 
snorting or sniffing its powder, or liquid, form. Onset is almost 
immediate, as the drug particles are able to cross the mucosal 
membranes within the nose and close to the brain.
RECTAL refers to the administration of a drug through the rectum 
with the use of suppositories. Suppositories are capsules that 
contain the substance powder, which can be easily administered 
rectally. The onset of effects is delayed as the capsule may take time 
to dissolve causing a delay of the absorption of the substance into 
the bloodstream.
SEDATIVE Any of a group of central nervous system depressants with the capacity 
of relieving anxiety and inducing calmness. Major classes of sedatives/
hypnotics include the benzodiazepines and barbiturates. See also 
hypnotic.
SIDE EFFECTS See adverse drug reaction.
STIMULANT In reference to the central nervous system (CNS), any agent that 
activates, enhances or increases neural activity; also called 
psychostimulants or CNS stimulants. Included are amphetamine-type 
stimulants, cocaine, caffeine, nicotine, etc. Other drugs have stimulant 
actions which are not their primary effect but which may be manifest in 
high doses or after chronic use.
TOLERANCE A decrease in response to a drug dose that occurs with continued use, 
i.e. increased drug doses are required to achieve the effects originally 
produced by lower doses.
TOXICOLOGY “Toxicology” is the science of substances as causes of side effects and 
disease in man, including their sources, appearance, chemical 
composition, properties, biological actions, detection and methods of 
treatment (antidotes). See also pharmacology.
TRANQUILLIZER A tranquillizer is a calming agent. The term can be used to differentiate 
between these drugs and the sedative/hypnotics: tranquillizers have a 
quieting or damping effect on psychomotor processes without—except at 
high doses—interference with consciousness or thinking.
WITHDRAWAL 
SYNDROME
A group of symptoms of variable clustering and degree of severity  
which occur on cessation or reduction of use of a psychoactive substance 
that has been taken repeatedly, usually for a prolonged period and/or in 
high doses.
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